H.C. Wainwright lowered the firm’s price target on Caribou Biosciences to $9 from $24 and keeps a Buy rating on the shares. The company presented updated results from the ANTLER trial which showed CB-010 results decline over time, the analyst tells investors in a research note. The firm says Caribou is now focusing on human leukocyte antigen matching between donor cells and patients in a bid to improve persistence. This course correction shall delay the start of a planned pivotal trial by at least six months, notes H.C. Wainwright.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBU:
- Caribou Biosciences Updates on CAR-T Therapy Trial and ASCO Presentation
- Caribou presents clinical data from CB-010 ANTLER Phase 1 trial
- Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences
- Caribou Biosciences (NASDAQ:CRBU): Riding The Ups and Downs of Biopharma Investing